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Abstract Human cerebrospinal fluid (CSF) sampling is
of high value as the only general applicable methodology
to obtain information on free drug concentrations in indi-
vidual human brain. As the ultimate interest is in the free
drug concentration at the CNS target site, the question is
what CSF concentrations may tell us in that respect.
Studies have been performed in rats and other animals for
which concentrations in brain extracellular fluid (brain
ECF) as a target site for many drugs, have been compared
to (cisterna magna) CSF concentrations, at presumed
steady state conditions,. The data indicated that CSF drug
concentrations provided a rather good indication of, but not
a reliable measure for predicting brain ECF concentrations.
Furthermore, comparing rat with human CSF concentra-
tions, human CSF concentrations tend to be higher and
display much more variability. However, this comparison
of CSF concentrations cannot be a direct one, as humans
probably had a disease for which CSF was collected in the
first place, while the rats were healthy. In order to be able
to more accurately predict human brain ECF concentra-
tions, understanding of the complexity of the CNS in terms
of intrabrain pharmacokinetic relationships and the influ-
ence of CNS disorders on brain pharmacokinetics needs to
be increased. This can be achieved by expanding a cur-
rently existing preclinically derived physiologically based
pharmacokinetic model for brain distribution. This model
has been shown to successfully predict data obtained for
human lumbar CSF concentrations of acetaminophen
which renders trust in the model prediction of human brain
ECF concentrations. This model should further evolute by
inclusion of influences of drug properties, fluid flows,
transporter functionalities and different disease conditions.
Finally the model should include measures of target site
engagement and CNS effects, to ultimately learn about
concentrations that best predict particular target site con-
centrations, via human CSF concentrations.
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Introduction
The treatment of neurological diseases is a huge problem.
The search for appropriate treatments is under increased
pressure as, on one hand, the results of drug candidates in
clinical trials are very disappointing, while on the other
hand an increase in the incidence of neurological diseases
is occurring, probably due to an ageing society and life
styles choices.
While having a significant effect in laboratory species,
the failure of central nervous system (CNS) drug candi-
dates in clinical phases may be caused by the drug candi-
date being given to the wrong subjects, administered at the
wrong dose or schedule, or because of the lack of proper
detection of the favorable effects of the CNS drug candi-
date. Thus, reasons for failure of CNS drug candidates can
at least in part be found in inconclusive pharmacokinetic
data, particularly regarding blood brain barrier (BBB)
transport, inconclusive pharmacodynamic data, and the
variability of the data due to the heterogenous nature of
CNS pathologies in humans [1]. Clearly, CNS drug
research so far has not yielded solutions and the question is
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how to have the right drug, at the right time, at the right
concentration, at the right place? To that end some main
issues need to be addressed:
• How to obtain information on (what can be referred to
as) the site of action in the CNS?
• How to appropriately diagnose neurological diseases,
especially in an early stage?
• How to determine the effect of the drug on treatment of
the disease?
To answer the first question, it is important to investi-
gate particular the free CNS drug concentrations, These
concentrations may serve as the best predictor of drug
effects because CNS drug targets such as receptors,
enzymes and transporters only interact with the free drug
concentration [2–10]. Emphasis has therefore been put on
obtaining reliable estimates of free drug concentrations in
the brain extracellular (brain ECF) space that faces many of
these targets [11]. The most straightforward method to
obtain information on free drug concentrations in human
brain ECF is by cerebrospinal fluid (CSF) sampling. CSF is
in close contact with brain ECF and therefore is expected to
reflect the brain ECF composition. Human CSF sampling
has been used (sparsely) for a long time as proof of CNS
penetration, for CSF biomarker evaluation, and for phar-
macokinetic-pharmacodynamic (PK-PD) modeling of CNS
drugs.
However, today, questions abound on the utility of
CSF sampling in neuroscience. It is therefore important to
critically evaluate the use of CSF drug concentrations as
source for information on brain ECF concentrations. The
literature provides many, mostly older, studies in which
CSF concentrations have been determined, and compared
with (total) plasma concentrations, mostly at single time
points, under assumed steady state conditions. With the
later introduction of the microdialysis technique, infor-
mation on the relationships between CSF concentrations
and brain ECF concentrations became available. Such
studies were typically performed in rodents because the
brain microdialysis technique is invasive, though mini-
mally [12]. In humans, this technique has only been
applied in extreme conditions such as brain trauma and
brain surgery. For ethical reasons it has never been used
in healthy volunteers (for details see Shannon et al. in this
special issue).
This article will provide information on brain compart-
ments from a physiological and anatomical perspective as
basis for interpretation of drug transport into and within the
brain. Studies will be presented in which CSF and brain
ECF concentrations have been assessed and compared,
followed by a systematic approach towards that leads to the
possibility to use human CSF values to predict target site
concentrations of CNS drugs [13].
CNS compartments and drug transport processes
Anatomy and physiology of the CNS
The anatomy of the CNS is complex. It can grossly be
divided into the following main compartments: brain
extracellular fluid (brain ECF), brain parenchyma (brain
cells), and the ventricular system. The ventricular system
can be seen as a communicating network of cavities filled
with CSF. It can be subdivided into the right and left lateral
ventricles, the third ventricle, the cerebral aqueduct, the
fourth ventricle, the cisterna magna, and the subarachnoid
space (Fig. 1). In humans, the subarachnoid CSF in the
lumbar region of the spinal cord (lumbar CSF) is of most
interest with regard to CSF sampling, because of its
accessability.
The exchange of substances from the brain ECF and
CSF are regulated by the blood–brain barriers, i.e., the
endothelial and epithelial interfaces that serve as barriers to
blood. The endothelial cells of the brain capillaries that
constitute the blood brain barrier (BBB) have tight junc-
tions in the paracellular space that render this cell layer
relatively impermeable to most hydrophilic molecules. In
addition a plethora of transport mechanisms are available
that control the exchange of compounds across the BBB
[14, 15].
The choroid plexus and arachnoidal epithelial cells
comprise the blood–CSF barrier (BCSFB). The BCSFB
also restricts and highly controlsthe exchange of com-
pounds. The BCSFB is comparable but quantitatively and
qualitatively not equal to the BBB [16–18]. More perme-
able capillaries are found in the circum ventricular organs
(CVOs), such as the subfornical organ in the third ventricle
region [19], than at the BBB.
CSF is continuously produced and eliminated. It pro-
vides a continuous circulation that acts more or less like a
brain drainage system (Fig. 2). Under normal circum-
stances the human brain produces *0.35 ml/min (500 ml/
day). The total volume of human CSF is *150 ml. This
indicates that the CSF turnover is *4 times/day [19].
Although the exact locations of CSF production are still
not clear there are known CSF production sites. The
majority of CSF is formed in the choroid plexus of
the lateral ventricles. Smaller amounts are formed by the
choroid plexus of the third and fourth ventricles. The
production is mediated by the filtration of plasma through
fenestrated capillaries and by active transport of water
and dissolved substances through the epithelial cells of
the BCSFB. In addition, there are indications that drain-
age of the brain ECF contributes to CSF formation [15].
Furthermore, it has been demonstrated that a substantial
portion of subarachnoid CSF cycles through the brain
interstitial space [20, 21]. Elimination of CSF takes place
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mostly via the granulations (kind of valves) of the
arachnoid villi, where CSF flows into the blood. This
process is driven by the hydrostatic pressure difference
between the CSF and the cerebral veins [22, 23]. In
addition, spinal venous reabsorption of CSF has been
proven to exist [24].
Fig. 1 Production, circulation
and resorption of cerebrospinal
fluid. The production of CSF
mostly takes place in the
choroid plexus of the ventricles.
CSF circulates from the
ventricles to the subarachnoid
spaces, where resorption takes
place via the arachnoid
granulations and villi during
circulation. From Kandel and
Schwartz, Principles of Neural
Science, Elsevier Science
Publishing, NY, 1985, with
permission
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Fig. 2 Simplifed and schematic representation of the production, flow and elimination of brain fluids
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In the rat these processes are similar although the par-
ticular physiological volumes and flow rates have different
values. Table 1 shows the values for both rat and human,
which is important in scaling by physiologically-based PK
modeling [25].
Processes that govern local pharmacokinetics of the free
drug in the CNS
Drug transport into, within, and out of the brain is governed
by the free drug concentrations in plasma, transport across
the brain barriers, CSF turnover and ECF bulk flow, extra-
intracellular exchange, brain tissue binding and brain drug
metabolism (Fig. 3). These processes have been exten-
sively addressed in previous publications [11, 16, 26–28].
It is important to note that transport across the blood–brain
barriers may occur by simple diffusion, facilitated diffu-
sion, vesicle transport, or active transport, or combinations
of these, depending on the drug. All these processes occur
concomitantly, and will influence each other’s rate and
extent, such that these interrelationships need to be con-
sidered in ultimately predicting CNS target site concen-
trations, and resulting drug effects [2, 29].
As many important CNS targets currently identified are
membrane bound receptors facing the brain ECF, the con-
centrations in this compartment are of high value in avail-
ability of the drug to interact with its CNS target. In order to
have the right drug at the right place at the right time in the
right concentrations, the drug properties and pharmacoki-
netic processes that govern drug concentrations at specific
CNS sites, must be known, ideally with measurements
included on target engagement and on drug effects.
What methods are available to obtain information
on unbound brain pharmacokinetic data?
For a long time, monitoring approaches have been searched
for that could be used to predict human target site kinetics
and (therewith) CNS effects. As it is the free drug that is
available for target binding, in the early 1980s it was
Table 1 Human and rat approximate values for brain physiological
parameters
Parameter Human value Rat value
CSF volume 150 ml [19] 250 ul [65]))
CSF production 0.35 ml/min [19] 2.2 ul/min
[66, 67]
CSF turnover 4 times/day [19] 11 times/day [19]
Brain weight 1400 g [68] 1.8 g (own
observations)
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Fig. 3 Simplified and schematic representation passive and active transport processes, metabolism, and fluid flow, that all govern the
concentration–time profile of the free drug at different sites in the CNS, and therewith CNS drug effects
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anticipated that CSF drug concentrations could serve as a
biomarker for free brain target site concentrations (with no
protein binding of drugs in CSF taking place at least under
physiological conditions) [30].
Single and repeated CSF sampling
The simplest way to study the entry of drugs into the CNS is to
measure drug concentrations in the lumbar CSF collected by a
single lumbar puncture during continuous intravenous infu-
sion. While CSF may not necessarily be equal to or closely
resembles CNS target site concentrations, this method pro-
vides information on the extent of drug distribution between
plasma and lumbar CSF. This may be useful knowledge, but
leaves out any information on time-dependency (rate) [31].
Via a permanent cannula in the cisterna magna, it is possible to
perform repeated (serial) CSF sampling in rats. Thus, the time-
course of concentrations in CSF can be obtained in parallelly
with CNS drug effects. This provides the possibility of within-
subject cross-over designed studies [32]. Also in humans
sequential repeated CSF sampling is possible [33]. By in
repeated CSF sampling, however, the constant withdrawal of
CSF may influence physiology. This is a concern and must be
taken into account [34].
Microdialysis
Microdialysis is a technique that is based on the constant
perfusion of a very small probe, with a tip that consists of a
semipermeable membrane. Molecules small enough to pass
this membrane will traverse the semipermeable membrane
towards the lowest concentration according to the con-
centration gradient. When placed into a tissue, molecules
from the extracellular space will enter the perfusate, which
becomes the dialysate that can be collected outside of the
subject, and can subsequently be analyzed on the com-
pound of interest by an analytical technique of choice, to
have information on the compound as a function of time in
the dialysate. Dialysate concentrations reflect the true
unbound PK in the extracellular fluid surrounding of the
microdialysis tip, which can be estimated after appropriate
correction for so called ‘‘in vivo recovery’’ [35–39].
To date no other technique is able to obtain such
quantitative and time resolved information on the unbound
drug of interest as by CSF sampling. However, while
minimally invasive to the brain of rats [12], the technique
is not widely applicable to human brain. Even the smallest
injury to the human brain made by choice should be
avoided, if it were not for substantial motifs in benefiting
the patient otherwise. Thus, microdialysis has been applied
frequently in trauma patients. Monitoring concentrations of
(e.g.) lactate and pyruvate as biological markers of brain
tissue injury in traumatic brain can be very helpful in the
judgement of the condition of the patient and to aid in
treatment decisions, well before being able to observe and
judge this on the basis of clinical assessments [40].
Microdialysis in human brain can also be combined with
neurosurgical procedures, for example before removal of
epileptogenic brain tissue. In such settings microdialysis
can also be used to measure brain penetration of drugs [41–
46], and provides the possibility to determine brain phar-
macokinetics in conjunction with resulting biochemical
efficacy of therapeutic approaches [40, 47, 48].
Because microdialysis, for obvious ethical reasons,
cannot be applied as a technique to be used in humans for
the purpose of drug development, human CSF is still
considered the best possible fluid to obtain from humans
that approximates unbound drug concentrations in brain
ECF [49]. The question remains how closely CSF con-
centrations reflect brain ECF concentrations in different
locations in the brain, in diseases, and for different drugs.
Available data on CSF–ECF relationships
With the introduction of microdialysis techniques, the
possibility of making a direct comparison of CSF and brain
ECF concentrations in animals became available. Also,
intrabrain distribution aspects of drugs could be deter-
mined. Sawchuk’s group at the University in Minnesota
was the first to do so. In rats, zidovudine and stavudine
concentration–time profiles were obtained in CSF and
Brain ECF, and challenged by inhibition of active transport
processes [50–52]. Shen et al. [27] provided an extensive
overview on CSF and brain ECF concentrations for drugs
from many therapeutic classes with a wide spectrum in
physico-chemical properties. Appending data of more
recent studies, Table 2 presents CSF -brain ECF relation-
ships for a broad set of drugs, including the methodology of
assessment. These values have resulted from microdialysis
to obtain brain ECF as well as CSF concentrations, CSF
sampling for assessing CSF concentrations, as well as he
brain slice method to obtain brain ECF concentrations. The
brain slice method estimates brain ECF concentrations by
determining total brain concentrations after drug adminis-
tration, and to correct for the free fraction as obtained in
brain slices after bathing the slice in a buffer solution
containing the drug(s) of interest [53, 54].
As a measure for the extent of distribution, the ‘‘Kpuu’’
value is used and defined as the ratio of the unbound tissue
(brain) concentration over the unbound plasma concentra-
tion, at equilibrium. Figure 4 shows the relationship of
observed data on Kpuu, CSF and Kpuu, brain, obtained
from the data presented in Table 2 for healthy rats, as well
as the relationship between rat and human Kpuu, CSF
values [55]. These figures clearly indicate that CSF con-
centrations in the healthy rat correlate rather well with
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Table 2 Drugs and their Kpuu, CSF and Kpuu, brain values obtained in animals (rats, sheep, rabbits, rhesus monkeys, and nonhuman primates)
on the basis of steady state (SS) values, AUC values, continuous infusion (cont inf)
Compound Species Time Kpuu, CSF Kpuu, brain Reference
9-OH-Risperidone Rat 6 h cont inf 0,0684 0,0143 [61]
Acetaminophen Rat AUC (partial) 0,3 1,2 [25]
Alovudine Rat SS 0,4 0,16 [72]
Antipyrine Rat 2 h cont inf 0,99 0,708 [56]
Atomoxetine Rat SS 1,7 0,7 [64]
Baclofen Rat Pseudo SS 0,028 0,035 [73]
Benzylpenicillin Rat 2 h cont inf 0,0134 0,0264 [56]
Buspirone Rat 2 h cont inf 0,558 0,612 [56]
Caffeine Rat 2 h cont inf 1,03 0,584 [56]
Carbamazepine Rat 2 h cont inf 0,535 0,771 [56]
Carbamazepine Rat 6 h cont inf 0,167 0,232 [61]
Carboplatin Nonhuman primate AUC 0,05 0,05 [74]
Cefodizime Rat Specific time 0,02 0,22 [75]
Ceftazidime Rat SS 0,039 0,022 [76]
Ceftriaxone Rat SS 0,71 0,8 [76]
Cephalexin Rat 2 h cont inf 0,0225 0,016 [56]
Cimetidine Rat 2 h cont inf 0,0211 0,00981 [56]
Cisplatin Nonhuman primate AUC 0,05 0,05 [74]
Citalopram Rat 2 h cont inf 0,667 0,494 [56]
Citalopram Rat 6 h cont inf 0,5 0,559 [61]
CP-615,003 Rat SS 0,01 0,0014 [77]
Daidzein Rat 2 h cont inf 0,189 0,0667 [56]
Dantrolene Rat 2 h cont inf 0,0838 0,0297 [56]
Diazepam Rat 2 h cont inf 0,847 0,805 [56]
Diphenylhydramine Sheep SS (adults) 3,4 3,4 [78]
Diphenylhydramine Sheep SS (30 d lambs) 4,9 6,6 [78]
Diphenylhydramine Sheep SS (10 d lambs) 5,6 6,6 [78]
EAB515 Rat 15 h 0,18 0,08 [51]
Flavopiridol Rat 2 h cont inf 0,216 0,0525 [56]
Fleroxacin Rat 2 h cont inf 0,283 0,25 [56]
Fleroxacin Rat SS 0,42 0,15 [79]
Ganciclovir Rat 6 h cont inf 0,0647 0,0711 [61]
Genistein Rat 2 h cont inf 0,589 0,181 [56]
Lamotrigine Rat SS 1,5 1 [62]
Loperamide Rat 2 h cont inf 0,0376 0,00886 [56]
Metoclopramide Rat 6 h cont inf 0,169 0,235 [61]
Midazolam Rat 2 h cont inf 1,35 2,19 [56]
Morphine Rat AUC 0,197 0,51 [80]
M6G Rat AUC 0,029 0,56 [80]
N-desmethylclozapine Rat 6 h cont inf 0,0151 0,01 [61]
Norfloxacin Rat SS 0,033 0,034 [79]
Ofloxacin Rat SS 0,23 0,12 [79]
Oxaliplatin Nonhuman primate AUC 0,65 5,3 [74]
Perfloxacin Rat 2 h cont inf 0,389 0,199 [56]
Perfloxacin Rat SS 0,37 0,15 [79]
Phenytoin Rat 2 h cont inf 0,396 0,447 [56]
Phenytoin Rat AUC 0,2 0,85 [81]
Probenecid Rat SS 0,6 0,2 [82]
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brain ECF concentrations although there is a trend for the
Kpuu, CSF values to be slightly larger than the Kpuu, brain
values. This may, at least in part, be due to more efficient
drug elimination from brain ECF by active efflux mecha-
nisms at the BBB, like mediated by P-glycoprotein (Pgp)
and breast cancer resistance protein (BCRP) [56].
The relationship between rat and human Kpuu, CSF is
more variable. There is a trend for human Kpuu, CSF to be
larger than rat Kpuu, CSF. One reason for this may be that
human CSF most probably has been obtained under disease
conditions. These conditions might have influenced blood–
brain transport, blood flow and/or metabolism, therewith
Table 2 continued
Compound Species Time Kpuu, CSF Kpuu, brain Reference
Quinidine Rat 2 h cont inf 0,0911 0,026 [56]
Quinidine Rat 6 h cont inf 0,0969 0,0459 [61]
Risperidone Rat 2 h cont inf 0,124 0,0787 [56]
Risperidone Rat 6 h cont inf 0,0913 0,0422 [61]
Salicylate Rat SS 0,5 0,1 [82]
SDZ EAA 494 Rat AUC 0,17 0,11 [83]
Sertraline Rat 2 h cont inf 0,832 1,85 [56]
Stavudine Rat SS 0,5 0,3 [84]
Stavudine Rat SS 0,6 0,6 [52]
Sulpiride Rat 2 h cont inf 0,0499 0,0219 [56]
Thiopental Rat 2 h cont inf 0,599 0,911 [56]
Thiopental Rat 6 h cont inf 0,0663 0,0663 [61]
Tiagabine Rat AUC 0,011 0,011 [85]
Verapamil Rat 2 h cont inf 0,333 0,0786 [56]
YM992 Rat SS 1,7 1,4 [86]
Zidovudin Rabbit AUC 0,17 0,08 [50]
Zidovudin Rabbit SS 0,29 0,19 [87]
Zidovudin Rhesus Monkey SS 0,27 0,15 [88]
Zidovudin ? probenecid Rabbit AUC 0,19 0,1 [50]
Zolpidem Rat 2 h cont inf 0,475 0,447 [56]
Fig. 4 a Relationship between the CSF/plasma unbound (Kpuu,
CSF) and brain ECF/plasma unbound ratios (Kpuu, brain) obtained at
presumed steady state conditions or by AUC comparisons) in healthy
animals for data depicted in Table 2, and b for rat versus human
Kpuu, CSF values (redrawn from Friden et al. (2009)). Note in b the
open circle representing a value for moxalactam obtained from a
healthy volunteer, and on the same horizontal line the half filled circle
representing a value for moxalactam obtained from a patient with
bacterial meningitis
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affecting the Kpuu values [43, 57, 58]. For moxalactam
there is some proof for this as one of the two human values
for Kpuu, CSF has been obtained under ‘‘normal’’ condi-
tions, and the other under ‘‘diseased’’ conditions (Fig. 4b),
[55]. Here, the ‘‘diseased’’ Kpuu, CSF was larger than the
‘‘healthy’’ Kpuu, CSF value. It may may very well be that
this Kpuu, CSF has reflected the corresponding Kpuu, brain
in humans, as is known for moxifloxacin in bacterial
meningitis [59]. In addition to the possibility of disease
influencing Kpuu, CSF, other factors such as the site of
CSF withdrawal and age of the patients may play a role
[58, 60].
There is one example of a study in which brain ECF,
brain tissue, CSF, and serum concentrations of antiepileptic
drugs were obtained intraoperatively from patients with
intractable epilepsy [45], and compared. Specifically, car-
bamazepine (CMZ), 10-hydroxy-carbazepine (10-OH-CZ,
the active metabolite of oxcarbazepine), lamotrigine
(LTG), and levetiracetam (LEV) were investigated. Overall
it was found that CSF concentrations were significantly
higher than corresponding brain ECF concentrations. This
ratio was *2.5 for CMZ, *3.5 for both 10-OH-CZ and
LEV, and *4.0 for LMT. This is extremely valuable
information, as this relationship has been shown for the
first time in human. For rats, under control conditions, the
CSF/brain ECF ratio for CMZ was *0.7 for two inde-
pendent studies [56, 61] and *1.5 for LMT [62].
Overall, it can be concluded that CSF drug concentra-
tions in rat, under controlled conditions, can give a rather
good indication, but not a reliable prediction of brain ECF
concentrations [3]. When it comes to humans, the condi-
tions of the human individuals are highly variable, such
that the relationship between rat CSF and human CSF
concentrations gets more scattered. But, apart from the
only study by Rambeck et al. [45], information about the
relation between human CSF and human brain ECF con-
centrations is still unavailable.
As human CSF is the only fluid that can be obtained
from human CNS, it is for that reason highly valuable and
new approaches to derive more information from human
CSF data are needed. To that end, much more mechanistic
insight is needed on the processes that govern intrabrain
distribution of drugs. This can be obtained from animal
studies, and combined with data on the relationship
between CSF and brain ECF concentrations from those
exceptional cases where microdialysis is allowed to be
used in individual patients.
Recently, Westerhout et al. [25] performed a series of
studies using a multiple microdialysis probe design in the
rat for measuring brain ECF concentrations and concomi-
tant CSF concentrations in the lateral ventricle and cisterna
magna (Fig. 5). Acetaminophen was the first paradigm
compound, representing a moderately lipophilic drug for
which only passive transport across the blood–brain bar-
riers and within the brain occurs. The data obtained were
used to build an advanced semi-physiological mathemati-
cal model of the brain, in which literature values of rat
brain physiology were incorporated (Fig. 6), This model
was able to describe the rat pharmacokinetic data in the
different brain compartments adequately. Interestingly,
after scaling the physiological parameters to the human
values, this model was able to predict available literature
data on human lumbar CSF concentrations [63]. This gave
much confidence in the model structure and values, as well
as in the prediction of brain ECF acetaminophen concen-
trations in human (Fig. 7). Recently, studies have been
performed with quinidine, as a moderately lipophilic Pgp
substrate. The Pgp inhibitor tariquidar was used to learn
more about the impact of specifically Pgp functionality
[REF, manuscript under revision, just accepted for
Fig. 5 Using the parallel
microdialysis probe design,
pharmacokinetics of drugs at
multiple sites in the brain can be
assessed in individual animals,
allowing direct comparison of
concentration–time profiles of
the free drug at these sites
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publication in JPKPD if revised]. Furthermore, studies
have been performed for methotrexate, as a hydrophilic
Mrp substrate, in which probenecid was used to study the
impact of MRP functionalities on brain distribution (yet
unpublished data).
Conclusions and perspectives
The development of drugs for CNS disorders has encoun-
tered high failure rates. In part this has been due to the sole
focus on BBB permeability of drugs, without taking into
account all other processes that determine drug concen-
trations at the target site. Moreover, conditional depen-
dence of these processes has typically been neglected. The
difficulty therefore relies in how to predict human brain
target site concentrations, which in many cases most clo-
sely relates to brain ECF concentrations. In human, the
only fluid that can be obtained is CSF.
So far it has been shown that in animals, under pre-
sumed steady state conditions, CSF concentrations tend to
overestimate brain ECF concentrations. No clear relation-
ship to the physicochemical properties of the drug could be
identified [27]. However, active efflux transport at the brain
ECF level for Pgp substrates seems to contribute to this
phenomenon [16, 55, 56]. When comparing rat CFS con-
centrations with human CSF concentrations, human CSF
concentrations tend to be higher and display much more
variability. It should also be considered that the comparison
here is made between healthy rats and humans that most
probably beared a (CNS) disease that invalidates any direct
comparison with healthy rats.
In order to be able to more accurately predict human
brain ECF concentrations, our understanding of CNS
complexity in terms of intrabrain pharmacokinetic rela-
tionships, brain distribution, and the influence of CNS
disorders needs to increase. This could be achieved by
performing more studies to obtain pharmacokinetic data in
parallel from brain ECF and CSF compartments in animals,
and building a generic PBPK model of brain distribution
[11, 25, 29, 64]. Such a model should include influences of
drug properties, fluid flows, transporter functionalities and
the influence of different disease conditions. Finally, the
free concentrations in different sites of the brain should be
connected to measures of target site engagement and CNS
effects to learn from best predictor concentrations for
particular targets.
CSF fluid is the only accessible fluid in the human CNS,
and for that reason is of high value. If the rat PBPK model
is scaled to humans and the model successfully predicts
human CSF concentration in the compartment where the
information was obtained from, this increases our trust in
the prediction of brain ECF concentrations using the model
[25, 89]. The model could also be refined by including
more ‘‘generating data—model prediction—model valida-
tion—confirm or adjust’’ cycles.
Fig. 6 Physiologically based pharmacokinetic model of brain distri-
bution, as derived for acetaminophen in the rat in which plasma, brain






















Fig. 7 Successfull prediction of unbound human plasma and lumbal
CSF (subarachnoid space, SAS), obtained by Bannwarth et al. [60], by
the preclinically derived PBPK model for acetaminophen, and predic-
tion of human brain ECF pharmacokinetics (Westerhout et al. [25])
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In summary, human CSF data can be of high value if we
have the knowledge that enables us to extrapolate the CSF
concentrations to brain target site concentrations, in order
to predict the CNS effect in individual human conditions.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
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